Psyence Biomedical Ltd (PBM)

$3.27 -0.08 (-2.39%)
Market Cap 1.86M
Revenue (ttm) 0.00
Net Income (ttm) 1.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 113,000
Avg Vol 2,039,504
Day's Range N/A - N/A
Shares Out 568,000.00
Stochastic %K 10%
Beta 0.22
Analysts Strong Buy
Price Target N/A

Company Profile

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress dis...

Industry: Biotechnology
Sector: Healthcare
Phone: 416-346-7764
Address:
121 Richmond Street West, Penthouse Suite, 1300, Toronto, Canada
TATTED_KEN
TATTED_KEN Aug. 15 at 2:08 PM
$PBM been watching this one. Took a small position $3.1s
0 · Reply
Zstock1981
Zstock1981 Aug. 15 at 12:44 AM
$PBM 🤡 blocked me🤣
1 · Reply
TTH21
TTH21 Aug. 14 at 7:50 PM
$PBM The push for federal legalization or marijuana, should/could provide some upward momentum here. No?
1 · Reply
MyPreciousShares
MyPreciousShares Aug. 14 at 7:22 PM
$PBM 500 shares traded threw this up 6% 😂 this name is so thin, any significant PR will catapult it again
0 · Reply
Ayan13
Ayan13 Aug. 14 at 3:56 PM
$PBM Why does this POS keeps going down
0 · Reply
onestudy
onestudy Aug. 14 at 2:26 PM
$PBMWW For new investors, $PBM / $PBMWW just announced that enrollment has officially begun for its Phase IIb clinical trial targeting Adjustment Disorder in oncology patients. 🚀🚀🚀🚀🚀
0 · Reply
Mangust05
Mangust05 Aug. 14 at 2:12 PM
$PBM you showed up ! Where were you ?
1 · Reply
JD101
JD101 Aug. 14 at 2:12 PM
$PBM there is life
0 · Reply
Mangust05
Mangust05 Aug. 14 at 3:48 AM
$PBM https://reason.org/psychedelics-policy/psychedelics-policy-newsletter-rfk-jr-gives-hopeful-approval-timeline-arizona-advances-ibogaine-and-more/
0 · Reply
Mangust05
Mangust05 Aug. 14 at 2:03 AM
$PBM https://youtube.com/shorts/CTmdpkf13Kg?si=yzwVAOluPkclSl3p. Under new administration I think Ibogaine and psilocybin will be legalized with few republican senators pushing this bill. 💎#FDA approval.
0 · Reply
Latest News on PBM
Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production

Jul 31, 2025, 7:30 AM EDT - 16 days ago

Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production

PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares

Jun 25, 2025, 5:00 PM EDT - 7 weeks ago

PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares

PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares

Jun 18, 2025, 5:36 PM EDT - 2 months ago

PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares

Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025

Jun 18, 2025, 8:30 AM EDT - 2 months ago

Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025

Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements

Jun 17, 2025, 8:00 AM EDT - 2 months ago

Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements

Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial

May 27, 2025, 7:30 AM EDT - 2 months ago

Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial

Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split

May 1, 2025, 7:30 AM EDT - 3 months ago

Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apr 17, 2025, 7:17 PM EDT - 4 months ago

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Psyence Group Announces Share Consolidation

Apr 17, 2025, 9:39 AM EDT - 4 months ago

Psyence Group Announces Share Consolidation

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

Apr 15, 2025, 8:30 AM EDT - 4 months ago

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia

Apr 8, 2025, 8:00 AM EDT - 4 months ago

Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia

Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing

Mar 31, 2025, 8:00 AM EDT - 4 months ago

Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing

Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

Mar 18, 2025, 8:30 AM EDT - 5 months ago

Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.

Mar 10, 2025, 11:18 AM EDT - 5 months ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.

Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.

Feb 26, 2025, 8:00 AM EST - 6 months ago

Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.

Psyence Biomed Announces Closing of $2.0 Million Private Placement

Dec 27, 2024, 4:05 PM EST - 8 months ago

Psyence Biomed Announces Closing of $2.0 Million Private Placement

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

Dec 23, 2024, 7:30 AM EST - 8 months ago

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Dec 17, 2024, 8:37 AM EST - 8 months ago

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial

Dec 17, 2024, 7:30 AM EST - 8 months ago

Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

Dec 10, 2024, 7:30 AM EST - 8 months ago

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

Dec 6, 2024, 11:06 AM EST - 9 months ago

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

Dec 3, 2024, 7:30 AM EST - 9 months ago

Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

Nov 19, 2024, 4:05 PM EST - 9 months ago

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

Nov 12, 2024, 4:30 PM EST - 9 months ago

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs

Oct 31, 2024, 9:30 AM EDT - 10 months ago

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Oct 25, 2024, 9:42 AM EDT - 10 months ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Oct 24, 2024, 7:00 AM EDT - 10 months ago

Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development

Oct 17, 2024, 7:00 AM EDT - 10 months ago

Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development

Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical

Oct 14, 2024, 10:43 AM EDT - 10 months ago

Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical

Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant

Oct 4, 2024, 4:05 PM EDT - 11 months ago

Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant

Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs

Sep 20, 2024, 11:20 AM EDT - 11 months ago

Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs

Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs

Sep 19, 2024, 7:30 AM EDT - 11 months ago

Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs

Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Sep 18, 2024, 9:30 AM EDT - 11 months ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

Sep 16, 2024, 9:31 AM EDT - 11 months ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Sep 16, 2024, 7:30 AM EDT - 11 months ago

Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq

Sep 13, 2024, 4:30 PM EDT - 1 year ago

Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq

Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant

Sep 6, 2024, 7:30 AM EDT - 1 year ago

Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant

Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC

Aug 30, 2024, 7:00 AM EDT - 1 year ago

Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC

Psyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Psyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024

Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development

Aug 13, 2024, 7:30 AM EDT - 1 year ago

Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development

Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

Jul 26, 2024, 9:30 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

Jul 24, 2024, 4:05 PM EDT - 1 year ago

Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

Psyence Biomedical Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Jul 3, 2024, 8:34 PM EDT - 1 year ago

Psyence Biomedical Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase

May 17, 2024, 7:00 AM EDT - 1 year ago

Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase

Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)

Apr 17, 2024, 8:00 AM EDT - 1 year ago

Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

Apr 16, 2024, 11:01 AM EDT - 1 year ago

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

Apr 8, 2024, 8:00 AM EDT - 1 year ago

Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business

Mar 26, 2024, 11:06 AM EDT - 1 year ago

Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business

TATTED_KEN
TATTED_KEN Aug. 15 at 2:08 PM
$PBM been watching this one. Took a small position $3.1s
0 · Reply
Zstock1981
Zstock1981 Aug. 15 at 12:44 AM
$PBM 🤡 blocked me🤣
1 · Reply
TTH21
TTH21 Aug. 14 at 7:50 PM
$PBM The push for federal legalization or marijuana, should/could provide some upward momentum here. No?
1 · Reply
MyPreciousShares
MyPreciousShares Aug. 14 at 7:22 PM
$PBM 500 shares traded threw this up 6% 😂 this name is so thin, any significant PR will catapult it again
0 · Reply
Ayan13
Ayan13 Aug. 14 at 3:56 PM
$PBM Why does this POS keeps going down
0 · Reply
onestudy
onestudy Aug. 14 at 2:26 PM
$PBMWW For new investors, $PBM / $PBMWW just announced that enrollment has officially begun for its Phase IIb clinical trial targeting Adjustment Disorder in oncology patients. 🚀🚀🚀🚀🚀
0 · Reply
Mangust05
Mangust05 Aug. 14 at 2:12 PM
$PBM you showed up ! Where were you ?
1 · Reply
JD101
JD101 Aug. 14 at 2:12 PM
$PBM there is life
0 · Reply
Mangust05
Mangust05 Aug. 14 at 3:48 AM
$PBM https://reason.org/psychedelics-policy/psychedelics-policy-newsletter-rfk-jr-gives-hopeful-approval-timeline-arizona-advances-ibogaine-and-more/
0 · Reply
Mangust05
Mangust05 Aug. 14 at 2:03 AM
$PBM https://youtube.com/shorts/CTmdpkf13Kg?si=yzwVAOluPkclSl3p. Under new administration I think Ibogaine and psilocybin will be legalized with few republican senators pushing this bill. 💎#FDA approval.
0 · Reply
TrdrEG
TrdrEG Aug. 13 at 9:23 PM
$PBM a lot of games being played in ah. things that make you go hmmmmm
0 · Reply
TrdrEG
TrdrEG Aug. 13 at 9:10 PM
$PBM free beer here tomorrow
0 · Reply
TrdrEG
TrdrEG Aug. 13 at 8:29 PM
$PBM not a good day, but a constructive one.
0 · Reply
Zstock1981
Zstock1981 Aug. 13 at 7:27 PM
$PBM where is the 🤡that pumped up to $100?🤣
0 · Reply
momjombo
momjombo Aug. 13 at 5:29 PM
$PBM Wow! What’s going on here? Let’s get the pumpers back in fast. Lol
0 · Reply
mcfaddenmn
mcfaddenmn Aug. 13 at 5:03 PM
$PBM in for 3000 more
0 · Reply
Ayan13
Ayan13 Aug. 13 at 3:41 PM
$PBM and it brought me down. Seriously !!!
0 · Reply
pc247cz
pc247cz Aug. 13 at 3:20 PM
$PBM Waiting for another opportunity to buy.
0 · Reply
goeagles1981
goeagles1981 Aug. 13 at 2:56 PM
$PBM No choice but to add more. I’m either going to be an A grade bagholder or come away with a nice chunk of change
0 · Reply
MyPreciousShares
MyPreciousShares Aug. 13 at 2:43 PM
$PBM Australian national news story on the Australia trial shared on PBM’s website https://psyencebiomed.com/channel-9-news-australia/
0 · Reply
MyPreciousShares
MyPreciousShares Aug. 13 at 2:41 PM
$PBM adding more here. Small float is volatile but good news is coming. There’s a lot of evidence the company is figuring out how to present its story and its progress, which will lead to share price gains over time
0 · Reply
TrdrEG
TrdrEG Aug. 13 at 2:16 PM
$PBM ill add a little more down here, but holding my nose while doing so.
0 · Reply